LT3972604T - Brutono tirozino kinazės inhibitorius, skirtas naudoti lėtinės spontaninės dilgėlinės gydymui - Google Patents

Brutono tirozino kinazės inhibitorius, skirtas naudoti lėtinės spontaninės dilgėlinės gydymui

Info

Publication number
LT3972604T
LT3972604T LTEPPCT/IB2020/054755T LTIB2020054755T LT3972604T LT 3972604 T LT3972604 T LT 3972604T LT IB2020054755 T LTIB2020054755 T LT IB2020054755T LT 3972604 T LT3972604 T LT 3972604T
Authority
LT
Lithuania
Prior art keywords
urtica
bruton
treatment
tyrosine kinase
kinase inhibitor
Prior art date
Application number
LTEPPCT/IB2020/054755T
Other languages
English (en)
Inventor
Souvik Bhattacharya
Bruno BIETH
Maciej CABANSKI
Bruno CENNI
Stefan De Buck
Martin Kaul
Arvind Kinhikar
Andrijana RADIVOJEVIC
Thomas Severin
Julian STORIM
Alessandra VITALITI GARAMI
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3972604T publication Critical patent/LT3972604T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/IB2020/054755T 2019-05-23 2020-05-20 Brutono tirozino kinazės inhibitorius, skirtas naudoti lėtinės spontaninės dilgėlinės gydymui LT3972604T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
LT3972604T true LT3972604T (lt) 2025-09-10

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2020/054755T LT3972604T (lt) 2019-05-23 2020-05-20 Brutono tirozino kinazės inhibitorius, skirtas naudoti lėtinės spontaninės dilgėlinės gydymui

Country Status (22)

Country Link
US (2) US12419889B2 (lt)
EP (2) EP4599894A3 (lt)
JP (2) JP7568651B2 (lt)
KR (1) KR20220012281A (lt)
CN (1) CN113795255A (lt)
AU (2) AU2020280272B2 (lt)
BR (1) BR112021022602A2 (lt)
CA (1) CA3138081A1 (lt)
CL (1) CL2021003032A1 (lt)
DK (1) DK3972604T3 (lt)
ES (1) ES3039974T3 (lt)
FI (1) FI3972604T3 (lt)
HR (1) HRP20251001T1 (lt)
IL (1) IL286983B2 (lt)
LT (1) LT3972604T (lt)
MX (2) MX2021013942A (lt)
PL (1) PL3972604T3 (lt)
PT (1) PT3972604T (lt)
RS (1) RS67141B1 (lt)
SI (1) SI3972604T1 (lt)
TW (1) TWI868139B (lt)
WO (1) WO2020234782A1 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3972604T3 (fi) * 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa

Also Published As

Publication number Publication date
AU2025252618A1 (en) 2025-11-06
TW202537625A (zh) 2025-10-01
IL286983B1 (en) 2025-09-01
HRP20251001T1 (hr) 2025-10-24
TWI868139B (zh) 2025-01-01
CN113795255A (zh) 2021-12-14
BR112021022602A2 (pt) 2022-01-04
DK3972604T3 (da) 2025-09-15
PL3972604T3 (pl) 2025-09-22
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
IL286983A (en) 2021-12-01
TW202110450A (zh) 2021-03-16
AU2020280272A1 (en) 2021-11-18
ES3039974T3 (en) 2025-10-28
SI3972604T1 (sl) 2025-09-30
JP7568651B2 (ja) 2024-10-16
EP3972604A1 (en) 2022-03-30
CL2021003032A1 (es) 2022-09-09
RS67141B1 (sr) 2025-09-30
US20220184074A1 (en) 2022-06-16
AU2020280272B2 (en) 2025-07-24
FI3972604T3 (fi) 2025-09-01
EP4599894A2 (en) 2025-08-13
KR20220012281A (ko) 2022-02-03
CA3138081A1 (en) 2020-11-26
EP4599894A3 (en) 2025-11-12
JP2024178168A (ja) 2024-12-24
US12419889B2 (en) 2025-09-23
WO2020234782A1 (en) 2020-11-26
EP3972604B1 (en) 2025-06-04
PT3972604T (pt) 2025-08-26
MX2021013942A (es) 2022-01-04
MX2024014626A (es) 2025-01-09
US20250375446A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
MX388457B (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
PL3972604T3 (pl) Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej
EA201990226A1 (ru) Способы и композиции для лечения миелофиброза
IL261249B1 (en) Dosage preparations containing Bruton's tyrosine kinase inhibitor
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
IL287745A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
WO2016109217A3 (en) Btk inhibitors
MX381994B (es) Inhibidor de janus quinasa.
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
EA201791946A1 (ru) Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
SI3609886T1 (sl) Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo
EA201692470A1 (ru) Фармацевтические комбинации
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
TW201613577A (en) Pharmaceutical combinations
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
IL284916A (en) Cyclic molecules as Bruton's tyrosine kinase inhibitors
EP3328380A4 (en) INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
HUE066609T2 (hu) Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra